EMA Authorised: Isturisa (osilodrostat phosphate) — Recordati Rare Diseases

View source ↗

Summary

The European Medicines Agency authorised Isturisa (osilodrostat) for the treatment of Cushing syndrome, with Recordati Rare Diseases as the marketing-authorisat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Isturisa (osilodrostat)

Snippet

Status: Authorised. Therapeutic area: Cushing Syndrome. MAH: Recordati Rare Diseases. Decision date: 18/11/2024. Orphan medicine